Clinical trial drug makers feel regulatory heat

Contract manufacturers are realizing that risk assessments demonstrating the absence of cross-contamination between products are essential for regulatory inspection.

By George Miller

Regulators are raising the bar for the majority of drugs in development, causing some problems for manufacturers but wreaking havoc with contract manufacturing organizations. CMOs


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.